Nvs stock price forecast in light of recent earnings beats

In light of recent earnings beats, the NVS stock price forecast points toward continued bullish sentiment, with a 12-month price target of $110 driven by robust pharmaceutical demand and favorable regulatory approvals. Yeah, absolutely. So I think GLP-1s are noted to have I think modest reductions of Lp(a). I mean the focus of this study is on patients that are much higher on the range of Lp(a) so the top quartile and the top decile, which we believe you need to have pretty substantial knockdown 70% to 90% of the Lp(a) levels 90% plus ideally that would then enable you to have the hopeful hope for at least the genetically validated efficacy benefit. So we don't believe GLP-1s alone or PCSK9s alone, PCSK9s also not done Lp(a), are going to be sufficient for this patient population that is at a very high risk of cardiovascular events due to their Lp(a) levels. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. With healthcare sector ETFs showing inflows, the NVS stock price forecast trends higher, implying possible valuation lift to $108–$110 amid strengthened R&D investments.